DR info

臨床試験数 : 13 / 薬物数 : 19 - (DrugBank : 5) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 10

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Dichlorphenamide
   National Center for Research Resources (NCRR)
      1992   Phase 3   NCT00004802   -
Lamotrigin actavis
   Grete Andersen
      2013   -   EUCTR2013-003309-24-DK   Denmark;
Lamotrigin ”Nordic Prime
   Rigshospitalet, department of Neurology
      2022   Phase 3   EUCTR2021-003784-94-DK   Denmark;
Lamotrigine
   Grete Andersen, MD
      2013   Phase 3   NCT01939561   Denmark;
Lamotrigine 25Mg Oral Tablet, Extended Release
   University College, London
      2021   Phase 3   NCT05017155   United Kingdom;
MEXILETINA CLORIDRATO
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2015   Phase 2   EUCTR2014-002627-10-IT   Italy;
MEXITIL*20CPS
   Dept. of Neurology - Univ. of Kansas Medical Center
      2010   -   EUCTR2009-011184-36-IT   Italy;United Kingdom;
Mexiletine
   Assistance Publique - Hôpitaux de Paris
      2011   Phase 3   NCT02336477   France;
   Dept. of Neurology - Univ. of Kansas Medical Center
      2010   -   EUCTR2009-011184-36-IT   Italy;United Kingdom;
   Radboud University
      2014   Phase 2   NCT02045667   Netherlands;
   Richard Barohn, MD
      2008   Phase 2   NCT00832000   Canada;Italy;United Kingdom;United States;
   Rigshospitalet, department of Neurology
      2022   Phase 3   EUCTR2021-003784-94-DK   Denmark;
   University College, London
      2021   Phase 3   NCT05017155   United Kingdom;
Mexitil
   Radboud University Nijmegen Medical Center
      2012   -   EUCTR2010-024026-38-NL   Netherlands;
Namuscla
   Rigshospitalet, department of Neurology
      2022   Phase 3   EUCTR2021-003784-94-DK   Denmark;
RILUZOLO TEVA - 50 MG COMPRESSE RIVESTITE CON FILM 90 COMPRESSE IN BLISTER AL/PVC
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2015   Phase 2   EUCTR2014-002627-10-IT   Italy;
Ranolazine
   Ohio State University
      2014   Phase 1   NCT02251457   United States;